Lixte Biotechnology (LIXT) Competitors $3.90 -0.16 (-3.94%) Closing price 04:00 PM EasternExtended Trading$3.93 +0.03 (+0.77%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. KLTO, NRXP, XCUR, KLRS, ALGS, KALA, ATHE, NBRV, RNXT, and CGTXShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Klotho Neurosciences (KLTO), NRx Pharmaceuticals (NRXP), Exicure (XCUR), Kalaris Therapeutics (KLRS), Aligos Therapeutics (ALGS), KALA BIO (KALA), Alterity Therapeutics (ATHE), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Its Competitors Klotho Neurosciences NRx Pharmaceuticals Exicure Kalaris Therapeutics Aligos Therapeutics KALA BIO Alterity Therapeutics Nabriva Therapeutics RenovoRx Cognition Therapeutics Klotho Neurosciences (NASDAQ:KLTO) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations. Which has more volatility and risk, KLTO or LIXT? Klotho Neurosciences has a beta of 10.9, suggesting that its share price is 990% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Which has stronger valuation and earnings, KLTO or LIXT? Lixte Biotechnology is trading at a lower price-to-earnings ratio than Klotho Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A-$6.15M-$0.36-2.16Lixte BiotechnologyN/AN/A-$3.59M-$1.29-3.02 Do insiders and institutionals have more ownership in KLTO or LIXT? 20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 26.7% of Klotho Neurosciences shares are held by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is KLTO or LIXT more profitable? Lixte Biotechnology's return on equity of 0.00% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -1,779.01% -275.01% Lixte Biotechnology N/A N/A -222.90% Does the media refer more to KLTO or LIXT? In the previous week, Lixte Biotechnology had 1 more articles in the media than Klotho Neurosciences. MarketBeat recorded 8 mentions for Lixte Biotechnology and 7 mentions for Klotho Neurosciences. Lixte Biotechnology's average media sentiment score of 0.28 beat Klotho Neurosciences' score of 0.27 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Klotho Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKlotho Neurosciences and Lixte Biotechnology tied by winning 5 of the 10 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.90M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-3.0220.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book16.258.608.826.15Net Income-$3.59M-$54.65M$3.25B$265.06M7 Day Performance-20.08%5.43%4.05%2.80%1 Month Performance18.18%6.75%4.32%1.68%1 Year Performance85.71%31.59%36.25%29.59% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology0.1813 of 5 stars$3.90-3.9%N/A+92.4%$10.90MN/A-3.024News CoverageEarnings ReportShort Interest ↑KLTOKlotho NeurosciencesN/A$1.03+3.2%N/AN/A$47.43MN/A-2.86N/ANews CoverageUpcoming EarningsNRXPNRx Pharmaceuticals3.2375 of 5 stars$2.74+0.7%$28.50+940.1%+33.2%$47.38MN/A-1.362News CoverageUpcoming EarningsAnalyst ForecastShort Interest ↓Gap UpXCURExicure2.0217 of 5 stars$7.48-1.6%N/A+1,315.0%$47.34M$500K-1.9650Earnings ReportShort Interest ↓Gap DownKLRSKalaris Therapeutics2.1306 of 5 stars$2.53-1.9%$3.00+18.6%N/A$47.31MN/A0.00110News CoverageEarnings ReportALGSAligos Therapeutics4.4403 of 5 stars$7.72-3.5%$70.00+806.5%-43.2%$47.29M$3.94M-0.4490News CoverageKALAKALA BIO4.0023 of 5 stars$7.34-1.5%$13.00+77.2%+31.4%$46.57M$3.89M-0.8830Earnings ReportATHEAlterity Therapeutics3.1172 of 5 stars$5.31+1.8%$12.00+126.2%+314.5%$46.39MN/A0.0010Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx3.326 of 5 stars$1.24+2.5%$7.25+484.7%+3.4%$45.35M$240K-3.106News CoverageNegative NewsEarnings ReportShort Interest ↓CGTXCognition Therapeutics3.4482 of 5 stars$0.73+1.6%$2.83+290.8%+106.8%$44.76MN/A-0.9820News CoverageEarnings ReportShort Interest ↓Analyst Revision Related Companies and Tools Related Companies KLTO Alternatives NRXP Alternatives XCUR Alternatives KLRS Alternatives ALGS Alternatives KALA Alternatives ATHE Alternatives NBRV Alternatives RNXT Alternatives CGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access